Recent geopolitical events are causing the pharma industry to consider its supply chain more carefully than ever. Highly developed pharma markets rely on foreign suppliers for their drugs, especially China and India. The COVID-19 pandemic, rising raw material and fuel costs, Russia's war against Ukraine, and other events are prompting industry conversations about drug shortages and supply chain security.
In this report, the publisher assesses the outlook for pharmaceutical supply chains over the next 12 months, to determine to what extent bio/pharmaceutical companies and their service providers are concerned, and whether they plan to “onshore” or “offshore” their manufacturing steps.
In this report, the publisher assesses the outlook for pharmaceutical supply chains over the next 12 months, to determine to what extent bio/pharmaceutical companies and their service providers are concerned, and whether they plan to “onshore” or “offshore” their manufacturing steps.
Scope
Who should buy this report?- This 36-page report gives important, expert insight you won't find in any other source. 17 figures throughout the report illustrate major points and trends. This report is required reading for:
- CMO executives who must have deep understanding of the pharmaceutical supply chain to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
- Overview of supply chain trends and key stakeholders' attitudes to onshoring and sourcing
- Detailed survey of industry plans to change sourcing strategy
- Analysis by geography, drug molecule type, company type, manufacturing step (active pharmaceutical ingredient, finished dose form, packaging)
Table of Contents
- About the Publisher
- Study Design
- Respondent Mix
- The Onshoring Question
- Other Supply Chain Challenges
- Key Findings
- Appendix
- Contact the Publisher
List of Figures
- Survey Respondent Mix: Company Geography
- Respondent Mix by Seniority Level
- Respondent Mix by Company Size
- Respondent Mix by Company’s Business Type
- Respondent Mix by Drug Portfolio
- The Pharma Supply Chain
- Supply Chain Evolution for API Over the Next 12 Months
- Reasons for Onshoring API Over the Next 12 Months
- Supply Chain Evolution for Finished Dose and Packaging Over the Next 12 Months
- Reasons for Onshoring Dose/Packaging Over the Next 12 Months
- FDA-Registered Facilities
- Onshoring Plans - by Drug Type (1)
- Onshoring Plans - by Drug Type (2)
- Onshoring - Will It Work? (1)
- Onshoring - Will It Work? (2)
- Challenges for the Next 12 Months - by Company Geography
- Challenges for the Next 12 Months - by Company Business Model
- Key Findings
